SR One Capital Management’s Zenas BioPharma ZBIO Stock Holding History

SR One Capital Management’s Portfolio ZBIO Stock Details ZBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$128M	Hold	5,037,854	–	–	12.31%	2
2026 Q1	$98.5M	Hold	5,037,854	–	–	10.76%	3
2025 Q4	$183M	Buy	5,037,854 +126,315	+3%	+$4.15M	25.9%	1
2025 Q3	$109M	Hold	4,911,539	–	–	15.77%	3
2025 Q2	$47.6M	Hold	4,911,539	–	–	10.32%	4
2025 Q1	$38.8M	Hold	4,911,539	–	–	9.97%	4
2024 Q4	$40.2M	Hold	4,911,539	–	–	9.81%	5
2024 Q3	$83.1M	Buy	+4,911,539	New	+$88.3M	16.66%	2

Other funds holding ZBIO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

RPSM

Royalty Pharma Sub-Manager New York $242M AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

SR One Capital Management's ZBIO Position: Q2 2026 in Review

SR One Capital Management held its Zenas BioPharma (ZBIO) position steady in Q2 2026 at 5,037,854 shares worth $128M. The position accounts for 12.31% of the portfolio, ranked #2.

SR One Capital Management first reported a position in ZBIO in Q3 2024 and has held it in 8 quarters since. The position peaked at $183M in Q4 2025. 144 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

SR One Capital Management held 5,037,854 shares of Zenas BioPharma worth $128M as of Q2 2026.
SR One Capital Management left its Zenas BioPharma share count unchanged in Q2 2026.
Zenas BioPharma made up 12.31% of SR One Capital Management's portfolio in Q2 2026, its #2 holding.
SR One Capital Management first reported a position in Zenas BioPharma in Q3 2024 and has held it in 8 quarters since.
SR One Capital Management's Zenas BioPharma position peaked at $183M in Q4 2025.
144 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on SR One Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.